World Health Organization Declares Cannabis Compound CBD Safe.

The W.H.O declares CBD safe.
The World Anti-Doping Agency removed CBD from its 2018 prohibited substances list.
Cannliv Colorado LLC is now fully operational in Denver.
Cannliv connects the United States, South America, and Israel, setting exceptional standards in Hemp growth and exploration methods.
 
On December 14th, 2017, the World Health Organization (WHO), the international public health agency of the United Nations, officially supported cannabidiol (CBD), the relaxant compound of cannabis used in medical marijuana, stating, “not be internationally scheduled as a controlled substance.”
This news is fantastic for all CBD and Cannabis advocates throughout the world. As further research continues, we see many regions around the world-such as Israel, which has been called, “The Holy Land Of Medical Marijuana”-continually study the benefits and effects of Cannabis and the body.
Colorado has been a leader in the CBD research and development for years. There are, however, some adversities of Colorado. For a long time, the US Drug Enforcement Administration(DEA) has maintained that the non-psychoactive component of marijuana, cannabidiol, is a schedule I drug, classifying it as, “a drug that contains no trusted medical benefits and has a high potential for abuse.”
However, according to a preliminary report embraced by the WHO last week, the Expert Committee on Drug Dependence(ECDD) decided—and the WHO agreed—that clinical and pre-clinical studies of CBD have shown no evidence of potential abuse of the drug or experience any harms. Moreover, the experts have found plenty of indications that CBD has medical benefits, especially for treating epilepsy and that there’s “preliminary evidence” that CBD could be useful in treating Alzheimer’s disease, cancer, psychosis, Parkinson’s disease, and other severe conditions. Furthermore, the ECDD has declared that the current data “does not justify scheduling of cannabidiol.”
The WHO’s release also called for a fuller review of CBD in May 2018, when the ECDD will go through a more thorough review of cannabis and cannabis-related substances.
CBD and the Endocannabinoid System

CBD is thought to have a wide range of activities on the endocannabinoid system. When your body intakes CBD, it does not change the CB-receptors but instead interacts with other cannabinoid receptors that have been claimed to affect mood, appetite, pain, and inflammation.
Although researchers are still working out all of CBD’s functions, studies on animals and a small number of humans have found no evidence that it is toxic or addictive. It is a comparably safe compound that does not get the user “high” but helps regulate the endocannabinoid system. Further information is shown in the WHO report,
“There are two main cannabinoid (CB) receptors, CB1 which is primarily
located in the central nervous system with some expression in peripheral
tissues and CB2 receptors, which can be found in the periphery on cells with
immune function and in the gastrointestinal tract and at low densities in the
central nervous system.
       CBD does not appear to act directly at CB1 receptors, with a number of studies
reporting that there is no measurable response in binding assays. In studies
examining potential agonist effects at CB1 receptors, most find no effect, with
one report of a weak agonist and one of a weak antagonist effect, each at high
concentrations (>10uM). CBD also shows low affinity at CB2 receptors. [42]
       Across a range of measures in humans and animals, CBD had been shown to
have very different effects from those of THC. In mice, CBD failed to produce
the behavioral characteristics (e.g. suppression of locomotors activity,
hypothermia, antinociception) associated with CB1 activation, whereas THC
generated all of the effects which occur when CB1 is activated.”
(Published preliminary WHO report on CBD’s safety and benefits. [PDF])
Current standings on CBD

With the expanding data and the increasing acceptance of marijuana in the United States, CBD and other cannabis products are standing in the spotlight as the go-to medical alternative.
The World Anti-Doping Agency (WADA) removed CBD from its 2018 prohibited substances list. “Cannabidiol is no longer prohibited,” said WADA in its September 29 statement. However, without federal sanction and regulation, many CBD products—especially those sold online—can be mislabeled.
Not all CBD products are the same

Cannliv’s South America Hemp Forest: Cannliv’s core values begin with quality growth, superior extraction, and purity from the root. 
While CBD itself is safe and found to be helpful for many users, industry experts have warned that not all cannabis extracts are created equally, purely, or with the same methods of extraction.
Cannliv connects the United States, South America, and Israel, setting exceptional standards in hemp growth and exploration methods. Our growth and extraction methods have changed the hemp industry and surpassed current standards.
We believe in the cultivation of medical hemp for the production of natural, clean and user-friendly cannabinoid products that are crafted with the purest ingredients for a truly consistent and reliable source of hemp extract. Our scientists perform extensive cannabinoid profiling of our products, guaranteeing our hemp is microbial- and pathogen-free. This comprehensive testing sets the standard for what patients should expect in quality and safety of their medicine.

(Part of Cannliv South America team taking quality control to a hands-on level)


We are proud to announce that Cannliv Colorado LLC is now fully operational in Denver.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *